Trial Profile
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bempedoic acid (Primary)
- Indications Hyperlipidaemia
- Focus Therapeutic Use
- Sponsors Esperion Therapeutics
- 01 May 2020 Results (N= 3369), meta-analysis of data pooled from 4 clinical trials assessing the effect of Bempedoic acid on serum uric acid, published in the Drug Safety
- 02 May 2013 Primary endpoint 'Reduction in LDL-cholesterol-level' has been met.
- 02 May 2013 Results presented at the Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB) 2013 Scientific Sessions and reported in a Esperion Therapeutics media release.